selective TGFβR1 kinase inhibitor

completed oral CV studies in higher species

from data mining of internal matter and opt.

ACS Med. Chem. Lett. 11, 172-178

Bristol-Myers Squibb, Princeton, NJ


BMS-986260 (Bristol Myers Squibb (BMS) oral in vivo selective TGF-beta-R1 kinase inhibitor)

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: